Development of the AI-RAD Diagnostic Assistance Platform
First written in FY2020. 14 of 17 entries say "Restated". Latest entry: 2026-08-05.
0 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「We are continuing initiatives to expand the business, including adding functions to the “AI-RAD” artificial intelligence engine platform that assists image diagnosis and preparations to fully launch operations in Asia.」
The Company reiterated that it is continuing to add functionality to AI-RAD and prepare for expansion into Asia. No new milestones, such as regulatory approval or the launch of service provision, are reported. - FY2025RestatedAnnual report
「We are developing the AI-RAD diagnostic assistance platform, which will enable a diagnostic assistance engine using AI technology centered on deep learning to be used in daily image interpretation.」
Development of AI-RAD is continuing. No new milestones, such as regulatory approval or the launch of service provision, are reported. - FY2024-Q3RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including adding functions to the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business overseas.」
The Company reiterated that it is continuing to add functionality to AI-RAD and prepare for overseas expansion, but does not indicate any new completion or implementation milestones. - FY2024-Q2RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including adding functions to the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business overseas.」
The Company reiterated that it is continuing to add functionality to AI-RAD and prepare for overseas expansion, but does not indicate any new completion or implementation milestones. - FY2024-Q1RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including adding functions to the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business overseas, including China.」
The Company reiterated that it is continuing to add functionality to AI-RAD, but does not indicate any new completion or implementation milestones. - FY2023-Q3RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including adding functions to the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business in China.」
The Company reiterated that it is continuing to add functionality to AI-RAD, but this filing does not indicate any new completion or implementation milestones. - FY2023-Q2RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including adding functions to the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business in China.」
The Company reiterated that it is continuing to add functionality to AI-RAD, but this filing does not indicate any new completion or implementation milestones. - FY2023-Q1AdvancedAnnual report
「The company continues to pursue initiatives to expand the business, including adding functions to the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business in China.」
The Company stated that it is proceeding with additional functionality for AI-RAD, in addition to its ongoing development and practical implementation. - FY2022RestatedAnnual report
「The chest X-ray pneumonia detection AI engine (COVID-19), which received Japan’s first regulatory approval in December 2021, is now being provided through the AI-RAD artificial intelligence engine platform.」
The Company reiterated the regulatory approval and launch of the service on AI-RAD, previously reported, as full-year research and development and business initiatives. - FY2022-Q3AdvancedAnnual report
「The Company also obtained Japan’s first regulatory approval for a chest X-ray pneumonia detection AI engine (COVID-19) and began providing and selling services through the AI-RAD artificial intelligence engine platform, continuing to expand its services in the teleradiology field.」
The Company reported specific progress consisting of obtaining Japan’s first regulatory approval for a chest X-ray pneumonia detection AI engine and beginning to provide and sell the service through AI-RAD. - FY2022-Q2RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including developing the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, toward practical application, and preparing for the full-scale development of its business in China.」
The Company reiterated that development toward the practical application of AI-RAD is continuing, but provided no specific progress on completion or implementation. - FY2022-Q1RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including developing the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business in China.」
The Company reiterated that development of AI-RAD is continuing, but provided no specific progress on completion or implementation. - FY2021-Q3RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including developing the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business in China.」
The Company reiterated that development of AI-RAD is continuing, but provided no specific progress on completion or implementation. - FY2021-Q1RestatedAnnual report
「The company continues to pursue initiatives to expand the business, including developing the AI-RAD artificial intelligence engine platform, which assists with image diagnosis, and preparing for the full-scale development of its business in China.」
The Company reiterated that development of AI-RAD is continuing, but provided no specific progress on completion or implementation. - FY2020First statedAnnual report
「We are developing the AI-RAD diagnostic assistance platform, which will enable a diagnostic assistance engine using AI technology centered on deep learning to be used in daily image interpretation.」
The Company recorded for the first time a development initiative to incorporate AI-based diagnostic assistance into image interpretation work using diagnostic imaging accumulated through teleradiology.